ArticleThe Journal of allergy and clinical immunology2020
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.
Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 432 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation
Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial
Who cites it
432 citing papers in PubMed, 5 syntheses or guidelines pooled it, 688 citations in OpenAlex.
- An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination.Human vaccines & immunotherapeutics · 2023Pooled it
- Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis.Clinical reviews in allergy & immunology · 2023Pooled it
- Identifying novel host-based diagnostic biomarker panels for COVID-19: a whole-blood/nasopharyngeal transcriptome meta-analysis.Molecular medicine (Cambridge, Mass.) · 2022Pooled it
- Innate immunity to SARS-CoV-2 infection: a review.Epidemiology and infection · 2022Pooled it
- Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Pooled it
- Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury.JCI insight · 2025Trial
- Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.Scientific reports · 2024Trial
- Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study.European journal of medical research · 2023Trial
- Polymerised type I collagen modifies the physiological network of post-acute sequelae of COVID-19 depending on sex: a randomised clinical trial.Clinical and translational medicine · 2023Trial
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection.Microbiology spectrum · 2026Article
- Admission Cytokine Profiling for ICU Mortality Prediction in Heterogeneous Acute Respiratory Failure: An Exploratory Cytokine Profiling Study.Diagnostics (Basel, Switzerland) · 2026Article
- Potential biomarkers differentiating major depression from bipolar disorder depressive episodes by Olink Proteomics.BMC psychiatry · 2026Article
- Association Between Periodontal Health Status and COVID-19 Severity: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Association between ABO blood groups and sepsis risk in severe burns: a retrospective cohort study.BMC infectious diseases · 2026Article
- Hyaluronan Ameliorates Viral Pneumonia in Mice and Humans by Inhibiting Transcription Factor E2F1.American journal of respiratory cell and molecular biology · 2026Article
- Article
- Principal component analysis of cytokine signature in COVID-19 and Long COVID.Frontiers in immunology · 2026Article
- Cytokines in cerebrospinal fluid combined with machine learning improve the diagnostic accuracy and predict the progression of neurosyphilis.Frontiers in immunology · 2026Article
372 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression.
objectiveWe sought to identify biomarkers for disease severity and progression of COVID-19.
methodsForty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data.
resultsLevels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ-induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ-induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99.
conclusionsIn this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.